Clinical stage oncology drug company Avacta Group plc (AIM:AVCT) reported on Monday that AffyXell, its joint venture with South Korean drug maker Daewoong Pharmaceutical, has expanded its strategic partnership with biopharmaceutical manufacturer GenScript ProBio.
AffyXell and GenScript ProBio entered into a strategic manufacturing partnership in December 2021. It covers AffyXell's first drug development programme and additional future programmes. The partnership includes process development and production of viral vectors required for the production of AffyXell's future cell therapy products. As part of this strategic alliance, GenScript has also now committed to take an equity position in AffyXell at a future funding round. The two companies will collaborate in the area of business development, including potential out-licensing.
AffyXell was established in January 2020 by Daewoong Pharmaceutical and Avacta to develop next-generation cell and gene therapies based on mesenchymal stem cells which incorporate Affimer immunotherapies. Avacta said this new class of stem cell therapy is designed to produce Affimer proteins, in situ in the body, that reduce inflammatory or autoimmune responses to the stem cell therapy, potentially enhancing therapeutic effects.
GenScript ProBio is part of Genscript Biotech Corporation (HKG:1548) and is a global contract development and manufacturing organisation that provides a platform for research and development of biological drugs, DNA plasmids and lentiviruses, as well as for clinical production of cell and gene therapy products.
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development